Kiniksa Pharmaceuticals International Plc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Kiniksa Pharmaceuticals International Plc (KNSA) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Kiniksa Pharmaceuticals International Plc vs Its Competitors
- TTM: Trailing 12-month revenue of 946M vs 437,888M combined for its competitors (0.2% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+20.9% annualized vs trailing 12 months), vs accelerating (+7.0%) for its tracked peer group.
- Growth: Kiniksa Pharmaceuticals International Plc generated 58.1% revenue growth year over year in Q3 2026, vs 12.5% for its competitors combined.
- Profitability: Its 16.6% net margin compares with 16.0% for the peer group.
- Scale: Kiniksa Pharmaceuticals International Plc ranks #45 of 545 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.1% of industry market cap.
- Peer revenue share: Kiniksa Pharmaceuticals International Plc accounted for 0.2% of combined revenue among its tracked peer group, up from 0.2% a year earlier.
- Peer differentiation: Revenue per employee of $2.58M compares with $0.94M for the peer group (2.7x).
- Structure: Kiniksa Pharmaceuticals International Plc operates in the following segments: Pharmaceutical Segment.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
KNSA Sales vs. its Competitors, Q3 2026
Kiniksa Pharmaceuticals International Plc reported revenue growth of 58.12 % year on year in Q3 2026, above its competitors' combined revenue growth of 12.49 %.
With a net margin of 16.56 %, Kiniksa Pharmaceuticals International Plc achieved higher profitability than its competitors (16.02 %).
Kiniksa Pharmaceuticals International Plc generated 0.24 % of the combined sales of its peer group, up from 0.17 % a year earlier.
API endpoints for this dataset
Kiniksa Pharmaceuticals International Plc vs. its Competitors, Q3 2026
Revenue growth, year on year
Net income growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Kiniksa Pharmaceuticals International Plc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Kiniksa Pharmaceuticals International Plc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Kiniksa Pharmaceuticals International Plc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (6) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (4) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Kiniksa Pharmaceuticals International Plc's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 8.9% year over year, combined, vs 58.1% for Kiniksa Pharmaceuticals International Plc. Kiniksa Pharmaceuticals International Plc's share of combined industry revenue moved from 0.04% to 0.05%, a gain of 0.02 percentage points.
Kiniksa Pharmaceuticals International Plc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Kiniksa Pharmaceuticals International Plc | Yes | Yes | Yes | No |
| Competitors combined (95) | ||||
| High-Confidence Competitors (1) | - | - | - | |
| Similar-Size Competitors (10) | ||||
| Similar Growth & Profitability (8) | 62.50 % (5 of 8) | 100.00 % (8 of 8) | 100.00 % (8 of 8) | 14.30 % (1 of 7) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
KNSA Stock Performance relative to its Competitors
KNSA Stock Performance relative to High-Confidence Competitors
KNSA Stock Performance relative to Similar-Size Competitors
KNSA Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Ventyx Biosciences Inc | 282.9% | Outperformed |
| 2 | Damora Therapeutics Inc | 282.9% | Outperformed |
| 3 | 180 Life Sciences Corp | 282.9% | Outperformed |
| 4 | Prelude Therapeutics Inc | 282.9% | Outperformed |
| 5 | Dianthus Therapeutics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Kiniksa Pharmaceuticals International Plc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Kiniksa Pharmaceuticals International Plc's Comment on Competition and Industry Peers
Publicly Traded Peers of Kiniksa Pharmaceuticals International Plc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Kiniksa Pharmaceuticals International Plc |
7,970.60 | 945.96 |
 Eli Lilly And Company |
1,209,663.60 | 86,462.00 |
 Johnson and Johnson |
676,352.29 | 99,335.00 |
 Beone Medicines Ltd |
612,622.08 | 6,128.24 |
 Abbvie Inc |
516,201.32 | 66,014.00 |
 Merck and Co Inc |
362,398.40 | 66,569.00 |
| SUBTOTAL | 4,982,920.01 | 727,214.64 |
Sign in to see all competitors of Kiniksa Pharmaceuticals International Plc.
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Kiniksa Pharmaceuticals International Plc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Kiniksa Pharmaceuticals International Plc's Competitors Named by the Company
Competitive relationships identified from Kiniksa Pharmaceuticals International Plc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| MedImmun | Company report | 85% |
| Trevi Therapeutics Inc | Company report | 85% |
| Bristol myers Squibb Company | Company report | 85% |
| Regeneron Pharmaceuticals Inc | Company report | 85% |
| Abbvie Inc | Company report | 85% |
| Horizon Therapeutics Public Limited Company | Company report | 85% |
| Eli Lilly And Company | Company report | 85% |
Company report basis, confidence, active dates and source counts for Kiniksa Pharmaceuticals International Plc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Kiniksa Pharmaceuticals International Plc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Kiniksa Pharmaceuticals International Plc | Pharmaceutical Segment 100.00 % |
| Eli Lilly And Company | Reportable 100.00 % |
| Johnson and Johnson | Oncology 29.93 % |
| Merck and Co Inc | Pharmaceutical segment 89.95 % |
| Amgen Inc | Reportable 100.00 % |
| Abbott Laboratories | Diabetes Care 16.79 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Kiniksa Pharmaceuticals International Plc.
Kiniksa Pharmaceuticals International Plc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Kiniksa Pharmaceuticals International Plc | 7,971 | 2,584,598 | 299,366 |
| Eli Lilly And Company | 1,209,664 | 1,729,240 | 551,594 |
| Johnson and Johnson | 676,352 | 705,504 | 114,311 |
| Beone Medicines Ltd | 612,622 | 510,686 | 54,642 |
| Abbvie Inc | 516,201 | 1,158,140 | 181,509 |
| Merck and Co Inc | 362,398 | 887,587 | 42,267 |
| PEERS TOTAL | 4,974,949 | 940,083 | 144,435 |
Sign in to see all peers for Kiniksa Pharmaceuticals International Plc.
Kiniksa Pharmaceuticals International Plc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Eli Lilly And Company | United States 62.04 % |
| Johnson and Johnson | United States 58.90 % |
| Beone Medicines Ltd | United States 54.39 % |
| Merck and Co Inc | EMEA 21.50 % |
| Abbott Laboratories | Non-US 57.70 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Kiniksa Pharmaceuticals International Plc.
Kiniksa Pharmaceuticals International Plc's Position in Industry Market Structure
Market-capitalization share and concentration across all 495 companies in Kiniksa Pharmaceuticals International Plc's industry classification, broader than the peer set above. Market cap in millions of $.Kiniksa Pharmaceuticals International Plc ranks #45 of 495 companies by market capitalization in its industry, holding 0.13 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 875, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,210,070 | 20.69 % |
| 2 | Johnson and Johnson | 674,004 | 11.53 % |
| 3 | Beone Medicines Ltd | 612,622 | 10.48 % |
| 4 | Abbvie Inc | 515,910 | 8.82 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Astrazeneca Plc | 1,234 | 5.2% |
| 45 | Kiniksa Pharmaceuticals International Plc | 7,828 | 0.13 % |
Market cap and industry share for the rest of Kiniksa Pharmaceuticals International Plc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-06.
Kiniksa Pharmaceuticals International Plc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 40 | Corcept Therapeutics Inc | 8,615 | -2.56 % |
| 41 | Arrowhead Pharmaceuticals Inc | 8,339 | 42.30 % |
| 42 | Pharming Group N v | 8,102 | -8.57 % |
| 43 | Praxis Precision Medicines Inc | 8,087 | 60.03 % |
| 44 | Alkermes Plc | 1,234 | 12.3% |
| 45 | Kiniksa Pharmaceuticals International Plc | 7,828 | 132.35 % |
| 46 | Redhill Biopharma Ltd | 1,234 | 12.3% |
| 47 | Rhythm Pharmaceuticals Inc | 1,234 | 12.3% |
| 48 | Cytokinetics Incorporated | 1,234 | 12.3% |
| 49 | Axsome Therapeutics Inc | 1,234 | 12.3% |
| 50 | Ligand Pharmaceuticals Incorporated | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Kiniksa Pharmaceuticals International Plc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-06. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Kiniksa Pharmaceuticals International Plc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (444 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 66.90 % | 37.89 % (avg) | +29.0 pp |
| Operating Margin | 13.79 % | industry median | +7.4 pp |
| EBITDA Margin | 15.86 % | -6.23 % (avg) | +22.1 pp |
| Capital Intensity (Capex / Revenue) | 0.17 % | 7.58 % (avg) | -7.4 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Kiniksa Pharmaceuticals International Plc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (444 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 56.2x | 26.6x | +29.6x |
| EV / EBITDA | 40.7x | 15.9x | +24.7x |
| P/B | 9.9x | 4.3x | +5.6x |
| Return on Equity | 17.27 % | industry aggregate | -7.92 % |
| Return on Invested Capital | 9.71 % | -9.83 % (avg) | 19.54 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Kiniksa Pharmaceuticals International Plc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | 22.74 % | 56.60 % | 60.09 % |
| Operating Margin | - | - | - | 4.44 % | -9.32 % | -10.78 % | 11.40 % |
| Return on Invested Capital | - | -27.83 % | -34.27 % | 1.72 % | -2.95 % | -5.03 % | 7.11 % |
| P/E | - | - | - | 5.8x | 91.3x | - | 53.5x |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Kiniksa Pharmaceuticals International Plc's Strategic Group Map
Kiniksa Pharmaceuticals International Plc is shown in red; its closest peers by combined growth, margin and ROIC are labeled. See Methodology: Strategic Group Map for how this chart is built.
Kiniksa Pharmaceuticals International Plc's trailing-12-month revenue growth of 58.2% and operating margin of 13.8% compares with an average of 61.4% growth and 11.8% margin across its 8 closest peers by combined growth, margin and ROIC -- Kiniksa Pharmaceuticals International Plc sits below that peer average on growth and above it on margin.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Kiniksa Pharmaceuticals International Plc's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Kiniksa Pharmaceuticals International Plc falls in the Dog quadrant: relative market share of 0.01x vs its largest competitor, in an industry growing revenue 8.2% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Kiniksa Pharmaceuticals International Plc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 875 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 0.17 % vs industry average 7.58 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Kiniksa Pharmaceuticals International Plc's dedicated Suppliers and Customers pages, not here.
Kiniksa Pharmaceuticals International Plc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Kiniksa Pharmaceuticals International Plc falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Kiniksa Pharmaceuticals International Plc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Operating margin 7.4 points above the industry median.
- Latest-quarter revenue run-rate is accelerating (+20.9% annualized vs trailing 12 months).
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Return on equity 7.9 points below the industry aggregate.
- Low relative market share vs the industry leader (0.01x).
Opportunities
- A meaningful share of competitors (48.90 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Kiniksa Pharmaceuticals International Plc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Kiniksa Pharmaceuticals International Plc | 0.93 | 3.86 | - |
| Eli Lilly And Company | 0.16 | 1.44 | 1.44 |
| Johnson and Johnson | 0.36 | 1.04 | 0.60 |
| Beone Medicines Ltd | 2.30 | 3.16 | 0.23 |
| Abbvie Inc | 0.19 | 0.79 | - |
| Merck and Co Inc | 0.40 | 1.46 | 1.01 |
Sign in to see all peers for Kiniksa Pharmaceuticals International Plc.
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Kiniksa Pharmaceuticals International Plc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Kiniksa Pharmaceuticals International Plc | Q3 2026 | +58.1 % | +156.8 % |
| Eli Lilly And Company | Q3 2026 | +38.6 % | +15.6 % |
| Johnson and Johnson | Q3 2026 | +5.9 % | -95.9 % |
| Beone Medicines Ltd | Q2 2026 | +29.7 % | +151.3 % |
| Abbvie Inc | Q3 2026 | +10.3 % | +2,143.6 % |
| Merck and Co Inc | Q2 2026 | +5.1 % | - |
| PEERS TOTAL | +11.4 % | -5.1 % |
Sign in to see all peers for Kiniksa Pharmaceuticals International Plc.
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Kiniksa Pharmaceuticals International Plc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Kiniksa Pharmaceuticals International Plc | Q3 2026 | +37.0 % | -73.2 % |
| Eli Lilly And Company | Q3 2026 | +30.7 % | +52.2 % |
| Johnson and Johnson | Q3 2026 | +10.9 % | +17.7 % |
| Beone Medicines Ltd | Q2 2026 | +6.4 % | -57.0 % |
| Abbvie Inc | Q3 2026 | -19.2 % | -21.0 % |
| Merck and Co Inc | Q2 2026 | +23.6 % | +16.9 % |
Sign in to see all peers for Kiniksa Pharmaceuticals International Plc.
Kiniksa Pharmaceuticals International Plc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Kiniksa Pharmaceuticals International Plc | 12.64% | 15.45% | 17.27% |
| Eli Lilly And Company | 21.24% | 32.00% | 83.65% |
| Johnson and Johnson | 8.06% | 10.53% | 19.55% |
| Beone Medicines Ltd | 7.82% | 10.32% | 14.24% |
| Abbvie Inc | 7.48% | 12.87% | - |
| Merck and Co Inc | 2.42% | 3.24% | 6.59% |
Sign in to see all peers for Kiniksa Pharmaceuticals International Plc.
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Kiniksa Pharmaceuticals International Plc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Kiniksa Pharmaceuticals International Plc | 71.65 | 8.43 |
| Eli Lilly And Company | 43.96 | 13.99 |
| Johnson and Johnson | 41.79 | 6.81 |
| Beone Medicines Ltd | 924.91 | 99.97 |
| Abbvie Inc | 50.14 | 7.82 |
| Merck and Co Inc | 118.32 | 5.44 |
| PEERS AVERAGE | 44.61 | 6.85 |
Sign in to see all peers for Kiniksa Pharmaceuticals International Plc.
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.